William E. Steinkrauss
Keine laufenden Positionen mehr
Vermögen: 45 328 $ am 31.03.2024
Profil
William E.
Steinkrauss worked as a Director-Technical Accounting & Reporting at OvaScience, Inc. from 2015 to 2016.
Prior to that, he was a Senior Manager-Technical Accounting at Cubist Pharmaceuticals LLC from 2012 to 2015.
Currently, he is the Chief Financial & Administrative Officer at Curis, Inc. starting from 2016.
Steinkrauss completed his undergraduate and graduate degrees from Boston College.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CURIS, INC.
0,07% | 31.07.2023 | 4 170 ( 0,07% ) | 45 328 $ | 31.03.2024 |
Ehemalige bekannte Positionen von William E. Steinkrauss
| Unternehmen | Position | Ende |
|---|---|---|
| CURIS, INC. | Director of Finance/CFO | 05.08.2022 |
OvaScience, Inc.
 OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | Corporate Officer/Principal | 01.08.2016 |
| CUBIST PHARMACEUTICALS INC | Corporate Officer/Principal | 01.05.2015 |
Ausbildung von William E. Steinkrauss
| Boston College | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CURIS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
OvaScience, Inc.
OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | Health Technology |
